Search results for " Vaccines"

showing 10 items of 472 documents

HSP-MOLECULAR CHAPERONES IN CANCER BIOGENESIS AND TUMOR THERAPY: AN OVERVIEW

2012

Molecular chaperones, many of which are heat-shock proteins (HSPs), are an important class of molecules with various functions. Pathological conditions in which chaperones become etiological and/or pathogenic factors are called chaperonopathies, and are classified into by defect, by excess, and by "mistake". In the latter case, the chaperone is structurally and functionally normal but paqrtecipates in pathwais that favor diseases, aòlthough in some cases the chaperone may have post-translational modifications that may lead it to change its location and function and, thus, to become pathogenic. For example, HSP-chaperones are involved in acrcinogenesis in various ways, so that some forms of …

Settore MED/18 - Chirurgia GeneraleCell Transformation NeoplasticSettore MED/09 - Medicina InternaSettore BIO/16 - Anatomia UmanaNeoplasmsmolecular chaperones chapoeronig system chaperonology chaperonopathy by mistake cancer HSP60 chaperonin chaperonopathy.AnimalsHumansMolecular Targeted TherapyCancer VaccinesHeat-Shock Proteins
researchProduct

Properties of modified hepatitis B virus surface antigen particles carrying preS epitopes

1995

The current hepatitis B virus (HBV) vaccines contain the small (S) and middle (M) viral envelope proteins in particulate form but lack the large (L) protein. Although these particles elicit protective immunity to HBV, inclusion of the immunogenic preS1 region of the L protein may enhance their efficacy. To present preS1-derived epitopes on secretable subviral particles we rearranged the HBV envelope ORF by fusing part or all of the preS1 region to either the N or C terminus of the S protein. Fusion of the first 42 residues of preS1 to either site allowed efficient secretion of the modified particles and rendered the linked sequence accessible at the surface of the particle. Conversely, fusi…

Signal peptideHepatitis B virusAntigenicityMyeloma proteinHeterologousmedicine.disease_causeEpitopeCell LineEpitopesMiceViral Envelope ProteinsViral envelopeVirologymedicineAnimalsHumansHepatitis B VaccinesCloning MolecularProtein PrecursorsHepatitis B virusMice Inbred BALB CVaccines SyntheticHepatitis B Surface AntigensbiologyVirionVirologyMolecular biologybiology.proteinAntibodyJournal of General Virology
researchProduct

Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.

2004

Background A genetic melanoma vaccine consisting of cDNA encoding the model self-antigen tyrosinase-related protein 2 (TRP2) fused in-frame to the immunogenic enhanced green fluorescent protein (EGFP) was able to break immune tolerance and stimulate CD8+ T cells in vivo. In the present study we investigated whether alteration of the intracellular antigen localization as a result of the linkage with immune-enhancing helper proteins affects the resulting immune response. Methods Expression plasmids and recombinant adenoviruses were constructed encoding various fusion proteins with different intracellular sorting signals which direct the antigen to the cytosol, the endoplasmic reticulum or the…

Skin Neoplasmsmedicine.medical_treatmentRecombinant Fusion ProteinsGenetic VectorsGreen Fluorescent ProteinsMelanoma ExperimentalAutoimmunityBiologyCancer VaccinesMelanoma VaccineImmune toleranceMiceImmune systemAntigenDrug DiscoveryGeneticsmedicineAnimalsMolecular BiologyGenetics (clinical)MelanomaELISPOTImmunotherapyGenetic TherapyT-Lymphocytes Helper-Inducermedicine.diseaseMolecular biologyFusion proteinCell biologyIntramolecular OxidoreductasesMice Inbred C57BLProtein TransportCD4 AntigensMolecular MedicineImmunizationThe journal of gene medicine
researchProduct

Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using c…

2011

Abstract The membrane-bound tumor-associated glycoprotein MUC1 is aberrantly glycosylated in cancer cells compared with normal cells, and is therefore considered an attractive target for cancer immunotherapy. However, tumor-associated glycopeptides from MUC1 do not elicit a sufficiently robust immune response. Therefore, antitumor vaccines were developed, which consist of MUC1 glycopeptides as the B epitopes and immune-stimulating toll-like receptor 2 (TLR 2) lipopeptide ligands. These fully synthetic vaccine candidates were prepared by solid-phase synthesis of the MUC1 glycopeptides. The Pam(3) Cys lipopeptide, also synthesized on solid-phase, was C-terminally coupled to oligovalent lysine…

Synthetic vaccineMagnetic Resonance SpectroscopyCarbohydrate chemistryMolecular Sequence DataAntineoplastic AgentsCancer VaccinesCatalysisEpitopeCell Linechemistry.chemical_compoundLipopeptidesMiceSolid-phase synthesisAnimalsHumansAntigens Tumor-Associated CarbohydrateVaccines SyntheticMembrane GlycoproteinsMolecular StructureOrganic ChemistryMucin-1GlycopeptidesLipopeptideGeneral ChemistryCombinatorial chemistryGlycopeptidechemistryClick chemistryClick ChemistryConjugateProtein BindingChemistry (Weinheim an der Bergstrasse, Germany)
researchProduct

Water-Soluble Polymers Coupled with Glycopeptide Antigens and T-Cell Epitopes as Potential Antitumor Vaccines

2013

Highly decorated: Tumor-associated MUC1 glycopeptide and tetanus toxoid T-cell epitope P2 can be attached to water-soluble poly(N-(2-hydroxypropyl)methacrylamide) carriers by orthogonal ligation techniques. Fully synthetic vaccine A with additional nanostructure-promoting domains induced antibodies that exhibit high affinity to tumor cells.

Synthetic vaccineMolecular Sequence DataEpitopes T-LymphocyteCancer VaccinesCatalysisEpitopeMicechemistry.chemical_compoundPolymethacrylic AcidsAntigenAnimalsHumansMethacrylamideAmino Acid SequenceMUC1Vaccines SyntheticbiologyMucin-1GlycopeptidesToxoidWaterT-Lymphocytes Helper-InducerGeneral ChemistryMolecular biologyGlycopeptideSolubilityBiochemistrychemistryMCF-7 Cellsbiology.proteinAntibodyAngewandte Chemie International Edition
researchProduct

A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral i…

2005

Synthetic vaccineT cellMolecular Sequence DataEpitopes T-LymphocyteCancer VaccinesCatalysisEpitopeImmune systemAntigenAntibody SpecificityAntigens NeoplasmmedicineCarbohydrate ConformationVaccines SyntheticChemistryMucin-1GlycopeptidesModels ImmunologicalStereoisomerismGeneral ChemistryGlycopeptidemedicine.anatomical_structureCarbohydrate SequenceImmunologyAntibody FormationSynthetic immunologyAngewandte Chemie (International ed. in English)
researchProduct

A Synthetic Vaccine Consisting of a Tumor-Associated Sialyl-TN-MUC1 Tandem-Repeat Glycopeptide and Tetanus Toxoid: Induction of a Strong and Highly S…

2009

Synthetic vaccineTransgeneMice TransgenicCancer VaccinesCatalysisMiceImmune systemTandem repeatAntigenAntigens NeoplasmTetanus ToxoidmedicineAnimalsHumansVaccines SyntheticMolecular StructureTetanusChemistryMucin-1GlycopeptidesToxoidGeneral Chemistrymedicine.diseaseVirologyPeptide FragmentsGlycopeptideImmune SystemAngewandte Chemie International Edition
researchProduct

Tumors as elusive targets of T-cell-based active immunotherapy.

2003

The understanding of tumor-host interactions remains elusive despite significant progress in the identification of tumor antigens (TAs) recognized by autologous T cells. In particular, most human tumors do not regress and continue to grow in spite of spontaneous or immunization-induced immune responses demonstrated in circulating lymphocytes. Indeed, systemic immune responses might insufficiently address the complexity of tumor-host interactions because of factors, such as (1) the lack of productive T-cell receptor (TCR) engagement with epitope owing to qualitative and/or quantitative defects in the generation and maintenance of the immune response, (2) insufficient costimulation provided b…

T cellmedicine.medical_treatmentT-LymphocytesImmunologyReceptors Antigen T-CellEpitopes T-Lymphocytechemical and pharmacologic phenomenaActive immunotherapyBiologyLymphocyte ActivationCancer VaccinesEpitopeImmune systemAntigenAntigens NeoplasmNeoplasmsmedicineImmunology and AllergyAnimalsHumansTumor microenvironmentImmunity CellularT-cell receptorImmunotherapy ActiveImmunotherapybiochemical phenomena metabolism and nutritionmedicine.anatomical_structureImmunologybacteriaTrends in immunology
researchProduct

Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles.

2005

Induction of high frequencies of specific T cells by vaccination requires prime-boost regimens. To reach optimal immune responses, it is necessary to use different vectors for priming and boosting as e.g. DNA vaccination followed by boosting with a recombinant viral vector. Here, we show that vaccines based on virus-like particles (VLP) displaying peptide epitopes are equally effective to induce CTL responses if used in a homologous or heterologous prime-boost setting. Strikingly, high frequencies (>20% of CD8(+) cells) of protective CTL could be induced and maintained by weekly injection of VLP. Thus, the use of VLP may avoid the requirement for complicated heterologous prime-boost regi…

T cellvirusesT-LymphocytesImmunologyT-cell vaccinationPriming (immunology)HeterologousEpitopes T-LymphocyteVaccinia virusBiologycomplex mixturesEpitopeViral vectorDNA vaccinationMicemedicineVaccines DNAVacciniaImmunology and AllergyAnimalsVaccinationVirionViral VaccinesVirologyHepatitis B Core AntigensCTL*medicine.anatomical_structureImmunologyCpG IslandsFemale
researchProduct

Unexpected Modulation of Recall B and T Cell Responses after Immunization with Rotavirus-like Particles in the Presence of LT-R192G

2010

LT-R192G, a mutant of the thermolabile enterotoxin of E. coli, is a potent adjuvant of immunization. Immune responses are generally analyzed at the end of protocols including at least 2 administrations, but rarely after a prime. To investigate this point, we compared B and T cell responses in mice after one and two intrarectal immunizations with 2/6 rotavirus-like particles (2/6-VLP) and LT-R192G. After a boost, we found, an unexpected lower B cell expansion measured by flow cytometry, despite a secondary antibody response. We then analyzed CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) and CD4(+)CD25(+)Foxp3(-) helper T cells after in vitro (re)stimulation of mesenteric lymph node cells …

T-LymphocytesHealth Toxicology and Mutagenesismedicine.medical_treatmentT cellBacterial ToxinsDose-Response Relationship Immunologiclcsh:Medicinechemical and pharmacologic phenomenaBiologyToxicologyArticleregulatory T cellsEnterotoxinsMiceInterleukin 21Immune systemB-1a lymphocyteAdjuvants ImmunologicAntigenmedicineAnimalsIL-2 receptorCD25B cellB-LymphocytesMice Inbred BALB CB lymphocytemucosal immunizationEscherichia coli Proteinslcsh:RRotavirus VaccinesVirionFOXP3LT-R192Ghemic and immune systemsrotavirusmedicine.anatomical_structureFoxp3ImmunologyFemaleImmunizationAdjuvantToxins
researchProduct